Travere Therapeutics, Inc. - 8-K Filing
Sandra Calvin to retire as CAO and PAO of Travere Therapeutics in February 2027; John Torell expected to succeed her. (Items: 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Offi)
Tickers: $TVTX